ML-016 not checked

BrYet US, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“a pH-sensitive polymeric doxorubicin formulated in a nanoporous silicon microparticle”In the company’s words, NCT07723482 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor With Lung and/or Liver Involvement
Main trialPhase 1/2
“This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).”In the company’s words, NCT07723482 on ClinicalTrials.gov
Other names
iNPG-pDox

Other drugs for Advanced Solid Tumor With Lung and/or Liver Involvement

All 266 drugs for Advanced Solid Tumor With Lung and/or Liver Involvement

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Oct 2027 ML-016 in Advanced Cancer With Lung and/or Liver Involvement
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ML-016

Following is part of Solo: you see every change to ML-016 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in